Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dec 15 (Reuters) - Quince Therapeutics Inc : QNCX : 1.1800 +0.1500 +14.56%
GENEXTRA S.P.A. REPORTS 5.89% PASSIVE STAKE IN QUINCE THERAPEUTICS
Total Cash (mrq) 83.22M
Total Cash Per Share (mrq) 1.94
Total Debt (mrq) 61k
Book Value Per Share (mrq) 2.29
Shares Outstanding 42.87M
Float 31.07M
Shares Short (prior month Oct 30, 2023) 4 2.16M
We see more and more big shareholders, I think we will see 1.50 – 1.75 this week.
Well-capitalized into 2026 with ability to fully fund lead asset EryDex expected through Phase 3 trial under special protocol assessment (SPA) and to NDA submission
https://quincetx.com/pipeline/
time for a strong rebound
Dec 01, 2023 0.9100 1.0500 0.9100 1.0300 1.0300 1,362,700
Oct 31, 2023 0.9500 1.0000 0.8400 0.8900 0.8900 1,624,600
Sep 30, 2023 1.0770 1.2100 0.9300 0.9710 0.9710 1,406,800
Aug 31, 2023 1.3400 1.3600 1.0600 1.1200 1.1200 2,505,300
Jul 31, 2023 1.2100 1.3400 1.1700 1.3100 1.3100 3,672,400
Jun 30, 2023 1.4900 1.7000 1.0800 1.2000 1.2000 13,124,000
May 31, 2023 1.4900 1.6600 1.3500 1.5050 1.5050 1,769,200
Apr 30, 2023 1.5300 1.7400 1.3800 1.5000 1.5000 2,458,500
Mar 31, 2023 1.6100 1.9300 1.4300 1.5300 1.5300 6,290,800
Mar 01, 2023 0.9300 1.5800 0.7900 1.5600 1.5600 62,561,600
Jul 31, 2021 57.1100 121.9800 55.3000 96.3000 96.3000 8,573,500
Dec 15 (Reuters) - Quince Therapeutics Inc : QNCX : 1.1800 +0.1500 +14.56%
GENEXTRA S.P.A. REPORTS 5.89% PASSIVE STAKE IN QUINCE THERAPEUTICS
Total Cash (mrq) 83.22M
Total Cash Per Share (mrq) 1.94
Total Debt (mrq) 61k
Book Value Per Share (mrq) 2.29
Shares Outstanding 42.87M
Float 31.07M
Shares Short (prior month Oct 30, 2023) 4 2.16M
We see more and more big shareholders, I think we will see 1.50 – 1.75 this week.
Well-capitalized into 2026 with ability to fully fund lead asset EryDex expected through Phase 3 trial under special protocol assessment (SPA) and to NDA submission
https://quincetx.com/pipeline/
time for a strong rebound
Dec 01, 2023 0.9100 1.0500 0.9100 1.0300 1.0300 1,362,700
Oct 31, 2023 0.9500 1.0000 0.8400 0.8900 0.8900 1,624,600
Sep 30, 2023 1.0770 1.2100 0.9300 0.9710 0.9710 1,406,800
Aug 31, 2023 1.3400 1.3600 1.0600 1.1200 1.1200 2,505,300
Jul 31, 2023 1.2100 1.3400 1.1700 1.3100 1.3100 3,672,400
Jun 30, 2023 1.4900 1.7000 1.0800 1.2000 1.2000 13,124,000
May 31, 2023 1.4900 1.6600 1.3500 1.5050 1.5050 1,769,200
Apr 30, 2023 1.5300 1.7400 1.3800 1.5000 1.5000 2,458,500
Mar 31, 2023 1.6100 1.9300 1.4300 1.5300 1.5300 6,290,800
Mar 01, 2023 0.9300 1.5800 0.7900 1.5600 1.5600 62,561,600
Jul 31, 2021 57.1100 121.9800 55.3000 96.3000 96.3000 8,573,500
Dec 15 (Reuters) - Quince Therapeutics Inc (QNCX 7.96%):
GENEXTRA S.P.A. REPORTS 5.89% PASSIVE STAKE IN QUINCE THERAPEUTICS
Total Cash (mrq) 83.22M
Total Cash Per Share (mrq) 1.94
Total Debt (mrq) 61k
Book Value Per Share (mrq) 2.29
Shares Outstanding 42.87M
Float 31.07M
Shares Short (prior month Oct 30, 2023) 4 2.16M
Dec 01, 2023 0.9100 1.0500 0.9100 1.0300 1.0300 1,362,700
Oct 31, 2023 0.9500 1.0000 0.8400 0.8900 0.8900 1,624,600
Sep 30, 2023 1.0770 1.2100 0.9300 0.9710 0.9710 1,406,800
Aug 31, 2023 1.3400 1.3600 1.0600 1.1200 1.1200 2,505,300
Jul 31, 2023 1.2100 1.3400 1.1700 1.3100 1.3100 3,672,400
Jun 30, 2023 1.4900 1.7000 1.0800 1.2000 1.2000 13,124,000
May 31, 2023 1.4900 1.6600 1.3500 1.5050 1.5050 1,769,200
Apr 30, 2023 1.5300 1.7400 1.3800 1.5000 1.5000 2,458,500
Mar 31, 2023 1.6100 1.9300 1.4300 1.5300 1.5300 6,290,800
Mar 01, 2023 0.9300 1.5800 0.7900 1.5600 1.5600 62,561,600
Feb 01, 2023 0.9790 1.0900 0.8800 0.9280 0.9280 7,632,800
Jan 01, 2023 0.6450 1.4700 0.6370 0.9800 0.9800 72,008,400
Dec 01, 2022 0.7490 0.7600 0.5400 0.6370 0.6370 5,984,600
Oct 31, 2022 1.0000 1.0390 0.6500 0.7370 0.7370 5,404,500
Sep 30, 2022 1.3700 1.3700 0.8620 1.0000 1.0000 3,903,500
Aug 31, 2022 1.7300 1.7580 1.2000 1.3300 1.3300 4,722,200
Jul 31, 2022 1.9700 2.7170 1.6500 1.7600 1.7600 5,607,500
Jun 30, 2022 2.2700 2.5800 1.7820 1.9500 1.9500 6,220,200
May 31, 2022 2.6300 3.3500 2.1240 2.2200 2.2200 13,239,100
Apr 30, 2022 3.6800 4.0360 2.5500 2.5900 2.5900 9,053,400
Mar 31, 2022 6.1900 6.8000 3.5000 3.6600 3.6600 8,466,600
Mar 01, 2022 4.3900 6.6300 4.1600 6.1900 6.1900 11,176,500
Feb 01, 2022 6.1000 7.2800 3.7920 4.3500 4.3500 16,120,800
Jan 01, 2022 12.6200 13.7000 5.3100 6.0800 6.0800 25,090,900
Dec 01, 2021 13.0300 14.6900 10.7100 12.6200 12.6200 29,715,500
Oct 31, 2021 13.1500 18.6800 11.5400 13.0100 13.0100 58,732,900
Sep 30, 2021 91.5000 98.5000 12.4100 13.2000 13.2000 55,719,500
Aug 31, 2021 96.0400 101.7600 81.7000 91.6600 91.6600 4,687,000
Jul 31, 2021 57.1100 121.9800 55.3000 96.3000 96.3000 8,573,500
Dec 15 (Reuters) - Quince Therapeutics Inc (QNCX 7.96%):
GENEXTRA S.P.A. REPORTS 5.89% PASSIVE STAKE IN QUINCE THERAPEUTICS
Total Cash (mrq) 83.22M
Total Cash Per Share (mrq) 1.94
Total Debt (mrq) 61k
Book Value Per Share (mrq) 2.29
Shares Outstanding 42.87M
Float 31.07M
Shares Short (prior month Oct 30, 2023) 4 2.16M
Dec 01, 2023 0.9100 1.0500 0.9100 1.0300 1.0300 1,362,700
Oct 31, 2023 0.9500 1.0000 0.8400 0.8900 0.8900 1,624,600
Sep 30, 2023 1.0770 1.2100 0.9300 0.9710 0.9710 1,406,800
Aug 31, 2023 1.3400 1.3600 1.0600 1.1200 1.1200 2,505,300
Jul 31, 2023 1.2100 1.3400 1.1700 1.3100 1.3100 3,672,400
Jun 30, 2023 1.4900 1.7000 1.0800 1.2000 1.2000 13,124,000
May 31, 2023 1.4900 1.6600 1.3500 1.5050 1.5050 1,769,200
Apr 30, 2023 1.5300 1.7400 1.3800 1.5000 1.5000 2,458,500
Mar 31, 2023 1.6100 1.9300 1.4300 1.5300 1.5300 6,290,800
Mar 01, 2023 0.9300 1.5800 0.7900 1.5600 1.5600 62,561,600
Feb 01, 2023 0.9790 1.0900 0.8800 0.9280 0.9280 7,632,800
Jan 01, 2023 0.6450 1.4700 0.6370 0.9800 0.9800 72,008,400
Dec 01, 2022 0.7490 0.7600 0.5400 0.6370 0.6370 5,984,600
Oct 31, 2022 1.0000 1.0390 0.6500 0.7370 0.7370 5,404,500
Sep 30, 2022 1.3700 1.3700 0.8620 1.0000 1.0000 3,903,500
Aug 31, 2022 1.7300 1.7580 1.2000 1.3300 1.3300 4,722,200
Jul 31, 2022 1.9700 2.7170 1.6500 1.7600 1.7600 5,607,500
Jun 30, 2022 2.2700 2.5800 1.7820 1.9500 1.9500 6,220,200
May 31, 2022 2.6300 3.3500 2.1240 2.2200 2.2200 13,239,100
Apr 30, 2022 3.6800 4.0360 2.5500 2.5900 2.5900 9,053,400
Mar 31, 2022 6.1900 6.8000 3.5000 3.6600 3.6600 8,466,600
Mar 01, 2022 4.3900 6.6300 4.1600 6.1900 6.1900 11,176,500
Feb 01, 2022 6.1000 7.2800 3.7920 4.3500 4.3500 16,120,800
Jan 01, 2022 12.6200 13.7000 5.3100 6.0800 6.0800 25,090,900
Dec 01, 2021 13.0300 14.6900 10.7100 12.6200 12.6200 29,715,500
Oct 31, 2021 13.1500 18.6800 11.5400 13.0100 13.0100 58,732,900
Sep 30, 2021 91.5000 98.5000 12.4100 13.2000 13.2000 55,719,500
Aug 31, 2021 96.0400 101.7600 81.7000 91.6600 91.6600 4,687,000
Jul 31, 2021 57.1100 121.9800 55.3000 96.3000 96.3000 8,573,500
MULN: 0.1523 + 0.0218 (16.70%)
BREA, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- via IBN -- Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, today announces a Class 3 EV low cab forward delivery to NRTC Automation Group (“NRTC”) in Birmingham, Alabama. Mullen and NRTC originally announced the Class 3 purchase order on Aug. 28, 2023, with deliveries slated to begin in Q4 2023.
NRTC, an Alabama-based company with locations in South Carolina, Michigan and Ontario, is focused on providing turnkey automation, prototyping and production manufacturing solutions for the automotive industry. NRTC purchased Mullen’s all-electric Class 3 low cab forward, the Mullen THREE, as part of its vehicle fleet to be used in a variety of applications.
“NRTC has a great working relationship with the Mullen Team, and we are thankful to have been a part of all that's been achieved in getting the Mullen THREE build operation to the finish line,” said Dan Hill, chief operations officer, NRTC Automation Group. “We are excited to receive our first Mullen THREE for use in our South Carolina location and feel it will work perfectly for the shuttle runs from NRTC to local customer locations.”
Class 3 production is based out of Tunica, Mississippi, which is home to Mullen’s commercial vehicle assembly for both the Mullen ONE, Class 1 EV cargo van and the Mullen THREE, Class 3 EV cab chassis truck. Mullen began first deliveries of the Mullen THREE to Randy Marion on Sept. 28, 2023. Randy Marion received its North Carolina license to retail Mullen’s commercial EVs on Nov. 16, 2023, opening the ability of the dealership to conduct sales to customers like NRTC.
“We’re very proud of our Class 3 trucks and excited to fulfill our commitment to deliver the Mullen THREE to customers like NRTC,” said David Michery, CEO and chairman of Mullen Automotive.
About NRTC Automation Group
NRTC is an Alabama-based company and has been in the automation space for automotive manufacturing integration since 2012.
To learn more about the company, visit www.NRTCAutomation.com.
About Mullen
Mullen Automotive (NASDAQ: MULN) is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana.
To learn more about the Company, visit www.MullenUSA.com.
MULN: 0.1523 + 0.0218 (16.70%)
BREA, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- via IBN -- Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, today announces a Class 3 EV low cab forward delivery to NRTC Automation Group (“NRTC”) in Birmingham, Alabama. Mullen and NRTC originally announced the Class 3 purchase order on Aug. 28, 2023, with deliveries slated to begin in Q4 2023.
NRTC, an Alabama-based company with locations in South Carolina, Michigan and Ontario, is focused on providing turnkey automation, prototyping and production manufacturing solutions for the automotive industry. NRTC purchased Mullen’s all-electric Class 3 low cab forward, the Mullen THREE, as part of its vehicle fleet to be used in a variety of applications.
“NRTC has a great working relationship with the Mullen Team, and we are thankful to have been a part of all that's been achieved in getting the Mullen THREE build operation to the finish line,” said Dan Hill, chief operations officer, NRTC Automation Group. “We are excited to receive our first Mullen THREE for use in our South Carolina location and feel it will work perfectly for the shuttle runs from NRTC to local customer locations.”
Class 3 production is based out of Tunica, Mississippi, which is home to Mullen’s commercial vehicle assembly for both the Mullen ONE, Class 1 EV cargo van and the Mullen THREE, Class 3 EV cab chassis truck. Mullen began first deliveries of the Mullen THREE to Randy Marion on Sept. 28, 2023. Randy Marion received its North Carolina license to retail Mullen’s commercial EVs on Nov. 16, 2023, opening the ability of the dealership to conduct sales to customers like NRTC.
“We’re very proud of our Class 3 trucks and excited to fulfill our commitment to deliver the Mullen THREE to customers like NRTC,” said David Michery, CEO and chairman of Mullen Automotive.
About NRTC Automation Group
NRTC is an Alabama-based company and has been in the automation space for automotive manufacturing integration since 2012.
To learn more about the company, visit www.NRTCAutomation.com.
About Mullen
Mullen Automotive (NASDAQ: MULN) is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana.
To learn more about the Company, visit www.MullenUSA.com.
RSLS
After-Hours Volume 20,812,890
After-Hours High $0.423 + 74.80%
IRVINE, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of a PMA supplement for the company’s next generation, enhanced Lap-Band® 2.0 FLEX.
“PMA supplement approval for our next generation Lap-Band® 2.0 FLEX is a historic event for ReShape that is expected to be a key growth catalyst for the company’s Lap-Band® franchise,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “The enhanced Lap-Band® 2.0 FLEX development effort was physician-led with the goal of improving the patient experience. Compared to our current Lap-Band, the Lap-Band® 2.0 has a new feature called FLEX Technology, which acts as a relief valve, allowing larger pieces of food to more easily pass through the narrowed passage (or stoma), created by the band. Specifically, the band momentarily relaxes before returning to its resting diameter, therefore, minimizing discomfort caused by passage of large food pieces through the stoma. The Lap-Band® system is the safest and most durable weight loss option for obese patients and is ideal for those who are averse to medically managed weight loss and who opt for the only available anatomy preserving surgery. We are preparing for our U.S. product launch of the Lap-Band 2.0 FLEX and look forward to providing updates on our progress.”
“Based on my 20-year use of the Lap-Band®, over time, some patients have needed adjustments, particularly when related to urgent loosening to relieve food obstruction,” stated Christine Ren-Fielding, M.D., Professor of Surgery at NYU Grossman School of Medicine, Director of the NYU Langone Weight Management Program and Chief of the Division of Bariatric Surgery. “Lap-Band 2.0® FLEX will potentially remedy this issue because of the ability for self-correction, utilizing an internal reservoir system. In addition, multi-modal therapy is becoming a mainstay in the bariatric surgery field. GLP-1 agonists can be used to complement and augment weight loss after surgery to help prevent weight regain.”
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
RSLS
After-Hours Volume 20,812,890
After-Hours High $0.423 + 74.80%
IRVINE, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of a PMA supplement for the company’s next generation, enhanced Lap-Band® 2.0 FLEX.
“PMA supplement approval for our next generation Lap-Band® 2.0 FLEX is a historic event for ReShape that is expected to be a key growth catalyst for the company’s Lap-Band® franchise,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “The enhanced Lap-Band® 2.0 FLEX development effort was physician-led with the goal of improving the patient experience. Compared to our current Lap-Band, the Lap-Band® 2.0 has a new feature called FLEX Technology, which acts as a relief valve, allowing larger pieces of food to more easily pass through the narrowed passage (or stoma), created by the band. Specifically, the band momentarily relaxes before returning to its resting diameter, therefore, minimizing discomfort caused by passage of large food pieces through the stoma. The Lap-Band® system is the safest and most durable weight loss option for obese patients and is ideal for those who are averse to medically managed weight loss and who opt for the only available anatomy preserving surgery. We are preparing for our U.S. product launch of the Lap-Band 2.0 FLEX and look forward to providing updates on our progress.”
“Based on my 20-year use of the Lap-Band®, over time, some patients have needed adjustments, particularly when related to urgent loosening to relieve food obstruction,” stated Christine Ren-Fielding, M.D., Professor of Surgery at NYU Grossman School of Medicine, Director of the NYU Langone Weight Management Program and Chief of the Division of Bariatric Surgery. “Lap-Band 2.0® FLEX will potentially remedy this issue because of the ability for self-correction, utilizing an internal reservoir system. In addition, multi-modal therapy is becoming a mainstay in the bariatric surgery field. GLP-1 agonists can be used to complement and augment weight loss after surgery to help prevent weight regain.”
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
TAOP: 1.5000-0.0400 (-2.5974%)
52 Week Range 1.3800 - 10.2000
SHENZHEN, China, Dec. 11, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today announced the Company was awarded a RMB16.2 million contract to provide AI servers to Fuzhou Shenpeng Technology Co. Ltd. The Company expects to recognize the revenue from this contract by the first quarter of 2024.
Taoping has seen an uplift in its AI-related business as it benefits from the broader market growth and adoption across industries and end markets. In addition to providing essential AI servers, Taoping developed an integrated cloud-based solution that harnesses the power and flexibility of AI alongside the Company's robust new Cloud Nest AI platform. This proprietary intelligent data collection and analysis solution was designed to help customers uncover and accelerate valuable opportunities for smart operations and enhanced business management.
Taoping's Chairman and CEO, Mr. Lin Jianghuai, commented, "The rapid advancement and widespread adoption of AI are propelling forward at an astonishing pace. This presents transformative prospects across a wide array of industries, urging management teams to take notice and decide whether to evaluate and take advantage of these technological advances or risk potentially falling behind. Taoping dedicates significant resources to developing our AI product suite, which ranges from essential AI servers to our robust Cloud Nest AI platform, a platform that aims to provide customers with a powerful solution for intelligent data collection and analysis as they seek efficient ways to adopt AI solutions over the near term that can provide long-term benefits. As a result, we expect AI to become an even more meaningful contributor to our growth and profitability over the coming years."
About Taoping Inc.
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us on X.
All time low
MULLEN AUTOMOTIVE INC 0,1359 24.586.631 -8,18%
high this year: 107,4375
TAOP: 1.5000-0.0400 (-2.5974%)
52 Week Range 1.3800 - 10.2000
SHENZHEN, China, Dec. 11, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today announced the Company was awarded a RMB16.2 million contract to provide AI servers to Fuzhou Shenpeng Technology Co. Ltd. The Company expects to recognize the revenue from this contract by the first quarter of 2024.
Taoping has seen an uplift in its AI-related business as it benefits from the broader market growth and adoption across industries and end markets. In addition to providing essential AI servers, Taoping developed an integrated cloud-based solution that harnesses the power and flexibility of AI alongside the Company's robust new Cloud Nest AI platform. This proprietary intelligent data collection and analysis solution was designed to help customers uncover and accelerate valuable opportunities for smart operations and enhanced business management.
Taoping's Chairman and CEO, Mr. Lin Jianghuai, commented, "The rapid advancement and widespread adoption of AI are propelling forward at an astonishing pace. This presents transformative prospects across a wide array of industries, urging management teams to take notice and decide whether to evaluate and take advantage of these technological advances or risk potentially falling behind. Taoping dedicates significant resources to developing our AI product suite, which ranges from essential AI servers to our robust Cloud Nest AI platform, a platform that aims to provide customers with a powerful solution for intelligent data collection and analysis as they seek efficient ways to adopt AI solutions over the near term that can provide long-term benefits. As a result, we expect AI to become an even more meaningful contributor to our growth and profitability over the coming years."
About Taoping Inc.
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us on X.
AMRN: 0.7040-0.0460 (-6.13%)
after hours: $0.7899 (+12.20%)
GREENWICH, Conn., December 04, 2023--(BUSINESS WIRE)--Sarissa Capital Management LP ("Sarissa") today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):
Sarissa believes Amarin’s stock is significantly undervalued. We continue to believe in both the tremendous value of Vascepa/Vazkepa to cardiovascular patients worldwide and the market opportunity. We are very upset that the stock has remained low. We expect that over time that value will be reflected in the stock price. We hope that recent progress detailed below will cause the stock to begin to reflect the value we think it has.
We remain long-term shareholders and have been purchasing shares at these depressed prices, as will be detailed in tomorrow’s 13D filing. We have never sold any shares of Amarin and have only increased our position since we made the investment.
Since reconstituting the board nine months ago, Amarin has made significant progress to strengthen its business operations and corporate governance and to remake the company for shareholders:
Reorganizing the leadership team under new CEO Patrick Holt with his international leadership and turnaround operating experience
Streamlining the U.S. business to maximize cash flows
Reworking Europe’s commercial infrastructure and pricing and reimbursement activities to be more effective and cost-efficient in key markets
Achieving national reimbursement approvals and launches of Vazkepa in Europe, including in Spain, Netherlands, and Scotland, as well as in China through EddingPharm
Securing multiple international partnership deals, including in Australia/New Zealand, South Korea and Southeast Asia, to grow Vazkepa globally
In Sarissa’s experience, turning around companies takes time. We are pleased with the progress that Amarin has made to date and expect the value to be reflected in the stock price over time. We share all shareholders’ frustration in the low stock price.
AMRN: 0.7040-0.0460 (-6.13%)
after hours: $0.7899 (+12.20%)
GREENWICH, Conn., December 04, 2023--(BUSINESS WIRE)--Sarissa Capital Management LP ("Sarissa") today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):
Sarissa believes Amarin’s stock is significantly undervalued. We continue to believe in both the tremendous value of Vascepa/Vazkepa to cardiovascular patients worldwide and the market opportunity. We are very upset that the stock has remained low. We expect that over time that value will be reflected in the stock price. We hope that recent progress detailed below will cause the stock to begin to reflect the value we think it has.
We remain long-term shareholders and have been purchasing shares at these depressed prices, as will be detailed in tomorrow’s 13D filing. We have never sold any shares of Amarin and have only increased our position since we made the investment.
Since reconstituting the board nine months ago, Amarin has made significant progress to strengthen its business operations and corporate governance and to remake the company for shareholders:
Reorganizing the leadership team under new CEO Patrick Holt with his international leadership and turnaround operating experience
Streamlining the U.S. business to maximize cash flows
Reworking Europe’s commercial infrastructure and pricing and reimbursement activities to be more effective and cost-efficient in key markets
Achieving national reimbursement approvals and launches of Vazkepa in Europe, including in Spain, Netherlands, and Scotland, as well as in China through EddingPharm
Securing multiple international partnership deals, including in Australia/New Zealand, South Korea and Southeast Asia, to grow Vazkepa globally
In Sarissa’s experience, turning around companies takes time. We are pleased with the progress that Amarin has made to date and expect the value to be reflected in the stock price over time. We share all shareholders’ frustration in the low stock price.
Not the moment to sell
USEG: 1.14
Nov 10, 2023 1.2500
Nov 09, 2023 1.2600
Nov 08, 2023 1.2800
Nov 07, 2023 1.3700
Nov 06, 2023 1.4000
Nov 03, 2023 1.4400
Nov 02, 2023 1.4500
Nov 01, 2023 1.4700
Oct 31, 2023 1.4500
Oct 30, 2023 1.5500
STRATEGIC ALTERNATIVES
U.S. Energy’s Board of Directors has decided to initiate a formal review process to evaluate strategic alternatives for the Company. The Board of Directors and management team are committed to acting in the best interests of the Company, its stockholders and its stakeholders. There is no deadline or definitive timetable set for completion of the strategic alternatives review process and there can be no assurance that this process will result in the Company pursuing a transaction or any other strategic outcome. U.S. Energy does not intend to make any further public comment regarding the review of strategic alternatives until it has been completed or the Company determines that a disclosure is required by law or otherwise deemed appropriate.
ABOUT U.S. ENERGY CORP.
We are a growth company focused on consolidating high-quality producing assets in the United States with the potential to optimize production and generate free cash flow through low-risk development while maintaining an attractive shareholder returns program. We are committed to ESG stewardship and being a leader in reducing our carbon footprint in the areas in which we operate. More information about U.S. Energy Corp. can be found at www.usnrg.com.
Not the moment to sell
USEG: 1.14
Nov 10, 2023 1.2500
Nov 09, 2023 1.2600
Nov 08, 2023 1.2800
Nov 07, 2023 1.3700
Nov 06, 2023 1.4000
Nov 03, 2023 1.4400
Nov 02, 2023 1.4500
Nov 01, 2023 1.4700
Oct 31, 2023 1.4500
Oct 30, 2023 1.5500
STRATEGIC ALTERNATIVES
U.S. Energy’s Board of Directors has decided to initiate a formal review process to evaluate strategic alternatives for the Company. The Board of Directors and management team are committed to acting in the best interests of the Company, its stockholders and its stakeholders. There is no deadline or definitive timetable set for completion of the strategic alternatives review process and there can be no assurance that this process will result in the Company pursuing a transaction or any other strategic outcome. U.S. Energy does not intend to make any further public comment regarding the review of strategic alternatives until it has been completed or the Company determines that a disclosure is required by law or otherwise deemed appropriate.
ABOUT U.S. ENERGY CORP.
We are a growth company focused on consolidating high-quality producing assets in the United States with the potential to optimize production and generate free cash flow through low-risk development while maintaining an attractive shareholder returns program. We are committed to ESG stewardship and being a leader in reducing our carbon footprint in the areas in which we operate. More information about U.S. Energy Corp. can be found at www.usnrg.com.
ATER : 0.3218+0.0013 (+0.41%)
52 Week Range 0.2600 - 1.6830
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Squatty Potty, the toilet stool that positions people how nature intended, reducing their strain while eliminating, announced that select Squatty Potty toilet stools have launched in Walmart stores nationwide. Squatty Potty is a 100% owned brand of Aterian, Inc. (Nasdaq: ATER).
“Our partnership with Walmart represents a significant step forward in our previously announced omnichannel expansion of the Squatty Potty brand. Walmart's footprint offers unparalleled opportunities to educate consumers on the many benefits of using Squatty Potty,” said Phil Lepper, Chief Revenue Officer of Aterian. “We know people love their Squatty Potty and we added products to Walmart with the everyday consumer in mind, including a folding Squatty Potty for easy bathroom storage and a portable travel Squatty Potty for taking with you on the go.”
To find a Walmart store near you visit walmart.com.
About Squatty Potty
Squatty Potty is the number one way to go number two! Squatty Potty is uniquely designed to help users assume the squatting position while using the toilet in order to deliver fast and complete elimination with comfort and ease. By putting your body into a natural squat position on the toilet, both strain and time on the toilet are reduced. Over 8 million Squatty Potty products have sold worldwide with multiple styles to choose from. Squatty Potty has also been awarded the 2023 Corporate Impact Award by the Crohn’s & Colitis Foundation.
To discover more about Squatty Potty visit squattypotty.com
About Aterian, Inc.
Aterian, Inc. (Nasdaq: ATER) is a technology-enabled consumer product company that builds and acquires leading e-commerce brands with top selling consumer products, in multiple categories, including home and kitchen appliances, health and wellness and air quality devices. By leveraging its cloud-based platform, Artificial Intelligence Marketplace Ecommerce Engine (AIMEE™), the Company sells across the world's largest online marketplaces with a focus on Amazon and Walmart and on its own direct to consumer websites.
ATER : 0.3218+0.0013 (+0.41%)
52 Week Range 0.2600 - 1.6830
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Squatty Potty, the toilet stool that positions people how nature intended, reducing their strain while eliminating, announced that select Squatty Potty toilet stools have launched in Walmart stores nationwide. Squatty Potty is a 100% owned brand of Aterian, Inc. (Nasdaq: ATER).
“Our partnership with Walmart represents a significant step forward in our previously announced omnichannel expansion of the Squatty Potty brand. Walmart's footprint offers unparalleled opportunities to educate consumers on the many benefits of using Squatty Potty,” said Phil Lepper, Chief Revenue Officer of Aterian. “We know people love their Squatty Potty and we added products to Walmart with the everyday consumer in mind, including a folding Squatty Potty for easy bathroom storage and a portable travel Squatty Potty for taking with you on the go.”
To find a Walmart store near you visit walmart.com.
About Squatty Potty
Squatty Potty is the number one way to go number two! Squatty Potty is uniquely designed to help users assume the squatting position while using the toilet in order to deliver fast and complete elimination with comfort and ease. By putting your body into a natural squat position on the toilet, both strain and time on the toilet are reduced. Over 8 million Squatty Potty products have sold worldwide with multiple styles to choose from. Squatty Potty has also been awarded the 2023 Corporate Impact Award by the Crohn’s & Colitis Foundation.
To discover more about Squatty Potty visit squattypotty.com
About Aterian, Inc.
Aterian, Inc. (Nasdaq: ATER) is a technology-enabled consumer product company that builds and acquires leading e-commerce brands with top selling consumer products, in multiple categories, including home and kitchen appliances, health and wellness and air quality devices. By leveraging its cloud-based platform, Artificial Intelligence Marketplace Ecommerce Engine (AIMEE™), the Company sells across the world's largest online marketplaces with a focus on Amazon and Walmart and on its own direct to consumer websites.
YESSSSSSSSSSSSSSSSSSS
ASTC : 7.57
As of September 26, 2023, 1,682,286 shares = MKTCAP: 12.7M
AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE)
Financial Highlights & Fiscal Year Developments
• Astrotech’s consolidated balance sheet remains strong with $42.1 million in cash and cash equivalents and liquid investments which is anticipated to support our research and development, organic growth, and potential acquisition targets.
• Gross margin increased to 41% for the year compared to 22% in the prior period, due to a higher proportion of recurring revenue.
AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ: ASTC) announced today that its 1st Detect subsidiary has accepted another significant purchase order for seven of its TRACER 1000™ explosives trace detectors (ETDs), for an airport security checkpoint. The systems will be deployed in a European airport in Romania.
“We’re excited to begin Fiscal Year 2024 with increased sales and interest in the TRACER 1000 from the security checkpoint field. Based on the near-zero false alarm rate that mass spectrometry provides, we believe that the TRACER 1000 improves checkpoint efficiency and passenger throughput by reducing the need for time-consuming pat-downs,” said Thomas B. Pickens III, Chairman and Chief Executive Officer of 1st Detect.
The Astrotech Mass Spectrometer Technology™ (AMS Technology) drives the breakthrough TRACER 1000, the first certified ETD to employ mass spectrometry. Recognized as the gold standard in chemical detection, mass spectrometry has historically been too costly, bulky, and cumbersome to be used outside of the laboratory. Unlike other technologies, the AMS Technology works under ultra-high vacuum, which eliminates competing molecules that can impair the accuracy and quality of an analysis. The TRACER 1000 is inexpensive, small, and easy to use, with high resolution and near-zero false alarms. Due to its high sensitivity and rugged design, the TRACER 1000 is the only mass spectrometry-based ETD to have received European Civil Aviation Conference (ECAC) certification for both checkpoint and cargo security.
About Astrotech Corporation
Astrotech (Nasdaq: ASTC) is a mass spectrometry company that launches, manages, and commercializes scalable companies based on its innovative core technology through its wholly owned subsidiaries. 1st Detect develops, manufactures, and sells trace detectors for use in the security and detection market. AgLAB is developing chemical analyzers for use in the agriculture market. BreathTech is developing a breath analysis tool to screen for volatile organic compound metabolites that could indicate they may have a bacterial or viral infection. Astrotech is headquartered in Austin, Texas. For information, please visit www.astrotechcorp.com.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, the adverse impact of inflationary pressures, including significant increases in fuel costs, global economic conditions and events related to these conditions, including the ongoing wars in Ukraine and the middle east and the COVID-19 pandemic, the Company’s use of proceeds from the common stock offerings, whether we can successfully complete the development of our new products and proprietary technologies, whether we can obtain the FDA and other regulatory approvals required to market our products under development in the United States or abroad, whether the market will accept our products and services and whether we are successful in identifying, completing and integrating acquisitions, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings including the Company’s most recent Annual Report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. While we do not intend to directly harvest, manufacture, distribute or sell cannabis or cannabis products, we may be detrimentally affected by a change in enforcement by federal or state governments and we may be subject to additional risks in connection with the evolving regulatory area and associated uncertainties. Any such effects may give rise to risks and uncertainties that are currently unknown or amplify others mentioned herein. Although the Company believes the expectations reflected in its forward-looking statements are reasonable and are based on reasonable assumptions, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct. Moreover, such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to correct or update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The Board believes that BML’s aim is to realize a short-term gain at the expense of the Company’s other stockholders. The Board believes that BML’s strategy of potentially liquidating the Company, as stated in BML’s Schedule 13D, would result in unfair profits to BML at the expense of all other stockholders because the offer price of $17.25 per share is significantly less than the per share value of the Company’s cash and short-term equivalents. Consistent with its history involving other public companies, the Board believes BML is targeting Astrotech for liquidation because the market value of Astrotech’s common stock is less than the book value of its cash and short-term investments. If BML were to acquire the Company at $17.25 per share (excluding shares directly held by BML), BML would expend an aggregate $25 million for the remaining 87% of Company shares that it does not own, and BML would then own 100% of a Company with a value of $26.17 per share, based solely on the book value of the cash and short-term investments as of March 31, 2023. If BML were then to liquidate the Company shortly thereafter, BML would realize a gain on all of its shares that would represent a significant premium over what all other stockholders would receive based on the Proposal, to the sole benefit of BML.
YESSSSSSSSSSSSSSSSSSS
ASTC : 7.57
As of September 26, 2023, 1,682,286 shares = MKTCAP: 12.7M
AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE)
Financial Highlights & Fiscal Year Developments
• Astrotech’s consolidated balance sheet remains strong with $42.1 million in cash and cash equivalents and liquid investments which is anticipated to support our research and development, organic growth, and potential acquisition targets.
• Gross margin increased to 41% for the year compared to 22% in the prior period, due to a higher proportion of recurring revenue.
AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ: ASTC) announced today that its 1st Detect subsidiary has accepted another significant purchase order for seven of its TRACER 1000™ explosives trace detectors (ETDs), for an airport security checkpoint. The systems will be deployed in a European airport in Romania.
“We’re excited to begin Fiscal Year 2024 with increased sales and interest in the TRACER 1000 from the security checkpoint field. Based on the near-zero false alarm rate that mass spectrometry provides, we believe that the TRACER 1000 improves checkpoint efficiency and passenger throughput by reducing the need for time-consuming pat-downs,” said Thomas B. Pickens III, Chairman and Chief Executive Officer of 1st Detect.
The Astrotech Mass Spectrometer Technology™ (AMS Technology) drives the breakthrough TRACER 1000, the first certified ETD to employ mass spectrometry. Recognized as the gold standard in chemical detection, mass spectrometry has historically been too costly, bulky, and cumbersome to be used outside of the laboratory. Unlike other technologies, the AMS Technology works under ultra-high vacuum, which eliminates competing molecules that can impair the accuracy and quality of an analysis. The TRACER 1000 is inexpensive, small, and easy to use, with high resolution and near-zero false alarms. Due to its high sensitivity and rugged design, the TRACER 1000 is the only mass spectrometry-based ETD to have received European Civil Aviation Conference (ECAC) certification for both checkpoint and cargo security.
About Astrotech Corporation
Astrotech (Nasdaq: ASTC) is a mass spectrometry company that launches, manages, and commercializes scalable companies based on its innovative core technology through its wholly owned subsidiaries. 1st Detect develops, manufactures, and sells trace detectors for use in the security and detection market. AgLAB is developing chemical analyzers for use in the agriculture market. BreathTech is developing a breath analysis tool to screen for volatile organic compound metabolites that could indicate they may have a bacterial or viral infection. Astrotech is headquartered in Austin, Texas. For information, please visit www.astrotechcorp.com.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, the adverse impact of inflationary pressures, including significant increases in fuel costs, global economic conditions and events related to these conditions, including the ongoing wars in Ukraine and the middle east and the COVID-19 pandemic, the Company’s use of proceeds from the common stock offerings, whether we can successfully complete the development of our new products and proprietary technologies, whether we can obtain the FDA and other regulatory approvals required to market our products under development in the United States or abroad, whether the market will accept our products and services and whether we are successful in identifying, completing and integrating acquisitions, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings including the Company’s most recent Annual Report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. While we do not intend to directly harvest, manufacture, distribute or sell cannabis or cannabis products, we may be detrimentally affected by a change in enforcement by federal or state governments and we may be subject to additional risks in connection with the evolving regulatory area and associated uncertainties. Any such effects may give rise to risks and uncertainties that are currently unknown or amplify others mentioned herein. Although the Company believes the expectations reflected in its forward-looking statements are reasonable and are based on reasonable assumptions, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct. Moreover, such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to correct or update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The Board believes that BML’s aim is to realize a short-term gain at the expense of the Company’s other stockholders. The Board believes that BML’s strategy of potentially liquidating the Company, as stated in BML’s Schedule 13D, would result in unfair profits to BML at the expense of all other stockholders because the offer price of $17.25 per share is significantly less than the per share value of the Company’s cash and short-term equivalents. Consistent with its history involving other public companies, the Board believes BML is targeting Astrotech for liquidation because the market value of Astrotech’s common stock is less than the book value of its cash and short-term investments. If BML were to acquire the Company at $17.25 per share (excluding shares directly held by BML), BML would expend an aggregate $25 million for the remaining 87% of Company shares that it does not own, and BML would then own 100% of a Company with a value of $26.17 per share, based solely on the book value of the cash and short-term investments as of March 31, 2023. If BML were then to liquidate the Company shortly thereafter, BML would realize a gain on all of its shares that would represent a significant premium over what all other stockholders would receive based on the Proposal, to the sole benefit of BML.
Amarin AMRN: 0.7244
52 Week Range 0.6500 - 2.2300
Total Cash (mrq) 321M
Total Cash Per Share (mrq) 0.79
Shares Outstanding 407.91M
Float 376.19M
Book Value Per Share (mrq) 1.39
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
Amarin Corporation plc
Sun, November 12, 2023 at 3:00 PM GMT+1
In this article:
-- Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo --
-- Subgroup Almost Exclusively Comprised of Patients with Established Cardiovascular Disease --
-- Findings Continue to Reinforce the Scientific Data and Clinical Use of VASCEPA®/VAZKEPA® to Reduce Cardiovascular Risk --
-- Results Presented Today at the American Heart Association (AHA) Scientific Sessions 2023 and Simultaneously Published in the European Heart Journal Open --
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 12, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced results from new REDUCE-IT analyses showing that among statin-treated patients in a prespecified subgroup with history of Metabolic Syndrome, but without diabetes at baseline, the addition of VASCEPA/VAZKEPA (icosapent ethyl) significantly reduced the risk of first and total cardiovascular events. This subgroup was almost exclusively comprised of patients with established cardiovascular disease. The results were presented today at the American Heart Association (AHA) Scientific Sessions 2023, taking place November 11 – 13, 2023 in Philadelphia, PA and simultaneously published in the European Heart Journal Open.
More than 1 out of every 3 adult Americans have Metabolic Syndrome, a cluster of 3 or more of 5 risk factors: 1) waist circumference ≥40 inches [102 cm] in men and ≥35 inches [88 cm] in women, 2) blood pressure ≥130/85 mmHg, 3) glucose ≥100 mg/dL, 4) triglycerides ≥150 mg/dL, and 5) HDL-C <40 mg/dL in men and <50 mg/dL in women.
Among patients with Metabolic Syndrome but without diabetes at baseline (n=2866), those who were allocated to icosapent ethyl (IPE) treatment with a median follow-up time of 4.9 years experienced a 29% relative risk reduction for the primary composite endpoint, defined as cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina resulting in hospitalization (P <0.0001) (Absolute Risk Reduction [ARR]=5.9%; number needed to treat [NNT]=17) and a 41% reduction in total (first plus subsequent) events (P <0.0001) compared with placebo. The risk for the key secondary composite endpoint, defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was reduced by 20% (P=0.05) and there was a 27% reduction in fatal/nonfatal myocardial infarction (P=0.03), 47% reduction in urgent/emergent revascularization (P <0.0001) and 58% reduction in hospitalization for unstable angina (P <0.0001). Non-statistically significant reductions were observed in cardiac arrest (44%) and sudden cardiac death (34%).
The large relative and absolute risk reductions observed supports IPE as an important therapeutic option for patients with metabolic syndrome at high cardiovascular risk, despite lacking robust effects on any metabolic syndrome component.
“These subgroup findings provide us with valuable insight into the role icosapent ethyl may play in helping reduce the risk of cardiovascular events in patients with Metabolic Syndrome, but without concomitant diabetes, including those secondary prevention patients with established cardiovascular disease, a patient group particularly at high-risk of having another cardiovascular event,” said Michael Miller, M.D., cardiologist and Chief of Medicine, Corporal Michael J Crescenz Veterans Affairs Medical Center and Professor of Medicine, Hospital of the University of Pennsylvania in Philadelphia. “This is an area of growing concern for the medical community and for patients globally, given the steady rise in the number of patients with Metabolic Syndrome across the U.S. and around the world.”
Commenting on the findings, Amarin’s Chief Medical Officer Nabil Abadir said, “These data continue to reinforce the clinical value of IPE and expand the growing list of benefits attributable to the molecule, including secondary prevention patients such as those with prior myocardial infarction, percutaneous coronary intervention or coronary bypass grafting, chronic kidney disease, heart failure, and history of cigarette smoking.”
Limitations of these analyses, some of which are exploratory in nature, include the relatively small number of events in certain subgroups or for certain endpoints, such as cardiac arrest and sudden cardiac death. In addition, variation in subjective measures (e.g., waist circumference) may have affected classification of metabolic syndrome.
About Metabolic Syndrome
Metabolic Syndrome is a cluster of conditions that increase the risk of heart disease, stroke and Type 2 diabetes mellitus (T2DM). Metabolic Syndrome is defined as the presence of any three of the following five risk factors: increased blood pressure, high blood sugar, excess body fat around the waist, low HDL cholesterol, or elevated/high triglyceride levels.1 Metabolic Syndrome is increasingly common,1 and more than 1 out of 3 people in the United States have it. Metabolic Syndrome is not only associated with a two-fold increased risk of adverse cardiovascular disease (CVD) outcomes (e.g., myocardial infarction, stroke and CV mortality), even in the absence of T2DM, but in recent years has also been linked to a variety of pathogenic phenotypes including heart failure and renal insufficiency.2,3,4
About Cardiovascular Risk
Cardiovascular disease is the number one cause of death in the world. In the United States alone, cardiovascular disease results in 859,000 deaths per year,5 and the number of deaths in the United States attributed to cardiovascular disease continues to rise. In addition, in the United States there are 605,000 new and 200,000 recurrent heart attacks per year (approximately 1 every 40 seconds). Stroke rates are 795,000 per year (approximately 1 every 40 seconds), accounting for 1 of every 19 U.S. deaths. In aggregate, in the United States alone, there are more than 2.4 million major adverse cardiovascular events per year from cardiovascular disease or, on average, 1 every 13 seconds.
Controlling bad cholesterol, also known as LDL-C, is one way to reduce a patient’s risk for cardiovascular events, such as heart attack, stroke or death. However, even with the achievement of target LDL-C levels, millions of patients still have significant and persistent risk of cardiovascular events, especially those patients with elevated triglycerides. Statin therapy has been shown to control LDL-C, thereby reducing the risk of cardiovascular events by 25-35%.6 Significant cardiovascular risk remains after statin therapy. People with elevated triglycerides have 35% more cardiovascular events compared to people with normal (in range) triglycerides taking statins.7,8,9
About REDUCE-IT®
REDUCE-IT was a global cardiovascular outcomes study designed to evaluate the effect of VASCEPA in adult patients with LDL-C controlled to between 41-100 mg/dL (median baseline 75 mg/dL) by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides between 135-499 mg/dL (median baseline 216 mg/dL) and either established cardiovascular disease (secondary prevention cohort) or diabetes mellitus and at least one other cardiovascular risk factor (primary prevention cohort).
REDUCE-IT, conducted over seven years and completed in 2018, followed 8,179 patients at over 400 clinical sites in 11 countries with the largest number of sites located within the United States. REDUCE-IT was conducted based on a special protocol assessment agreement with FDA. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology.10 The primary results of REDUCE-IT were published in The New England Journal of Medicine in November 201811. The total events 12 and other publications can be found in the R&D section on the company’s website at www.amarincorp.com.
About VASCEPA®/VAZKEPA® (icosapent ethyl) Capsules
VASCEPA (icosapent ethyl) capsules are the first prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk despite being on statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed more than twenty million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, VASCEPA is approved and sold in Canada, China, Lebanon and the United Arab Emirates. In Europe, in March 2021 marketing authorization was granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA. In April 2021 marketing authorization for VAZKEPA (icosapent ethyl) was granted in Great Britain (applying to England, Scotland and Wales). VAZKEPA (icosapent ethyl) is currently approved and sold in Europe in Sweden, Denmark, Finland, Austria, the UK, Spain and the Netherlands.
Indications and Limitation of Use (in the United States)
VASCEPA is indicated:
As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and
established cardiovascular disease or
diabetes mellitus and two or more additional risk factors for cardiovascular disease.
As an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
Important Safety Information
VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.
VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter.
It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur.
VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin.
Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial fibrillation (5% vs 4%).
Common adverse reactions in the hypertriglyceridemia trials (incidence >1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%).
Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.
Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding.
FULL U.S. FDA-APPROVED VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.
Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about the potential for VASCEPA (marketed as VAZKEPA in Europe); beliefs about icosapent ethyl (IPE)’s potential role in helping reduce the risk of cardiovascular events in patients with Metabolic Syndrome, but without concomitant diabetes, as well as general beliefs about the safety and effectiveness of VASCEPA/VAZKEPA. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the full year ended 2022. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate. Availability of Other Information About Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin AMRN: 0.7244
52 Week Range 0.6500 - 2.2300
Total Cash (mrq) 321M
Total Cash Per Share (mrq) 0.79
Shares Outstanding 407.91M
Float 376.19M
Book Value Per Share (mrq) 1.39
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
Amarin Corporation plc
Sun, November 12, 2023 at 3:00 PM GMT+1
In this article:
-- Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo --
-- Subgroup Almost Exclusively Comprised of Patients with Established Cardiovascular Disease --
-- Findings Continue to Reinforce the Scientific Data and Clinical Use of VASCEPA®/VAZKEPA® to Reduce Cardiovascular Risk --
-- Results Presented Today at the American Heart Association (AHA) Scientific Sessions 2023 and Simultaneously Published in the European Heart Journal Open --
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 12, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced results from new REDUCE-IT analyses showing that among statin-treated patients in a prespecified subgroup with history of Metabolic Syndrome, but without diabetes at baseline, the addition of VASCEPA/VAZKEPA (icosapent ethyl) significantly reduced the risk of first and total cardiovascular events. This subgroup was almost exclusively comprised of patients with established cardiovascular disease. The results were presented today at the American Heart Association (AHA) Scientific Sessions 2023, taking place November 11 – 13, 2023 in Philadelphia, PA and simultaneously published in the European Heart Journal Open.
More than 1 out of every 3 adult Americans have Metabolic Syndrome, a cluster of 3 or more of 5 risk factors: 1) waist circumference ≥40 inches [102 cm] in men and ≥35 inches [88 cm] in women, 2) blood pressure ≥130/85 mmHg, 3) glucose ≥100 mg/dL, 4) triglycerides ≥150 mg/dL, and 5) HDL-C <40 mg/dL in men and <50 mg/dL in women.
Among patients with Metabolic Syndrome but without diabetes at baseline (n=2866), those who were allocated to icosapent ethyl (IPE) treatment with a median follow-up time of 4.9 years experienced a 29% relative risk reduction for the primary composite endpoint, defined as cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina resulting in hospitalization (P <0.0001) (Absolute Risk Reduction [ARR]=5.9%; number needed to treat [NNT]=17) and a 41% reduction in total (first plus subsequent) events (P <0.0001) compared with placebo. The risk for the key secondary composite endpoint, defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was reduced by 20% (P=0.05) and there was a 27% reduction in fatal/nonfatal myocardial infarction (P=0.03), 47% reduction in urgent/emergent revascularization (P <0.0001) and 58% reduction in hospitalization for unstable angina (P <0.0001). Non-statistically significant reductions were observed in cardiac arrest (44%) and sudden cardiac death (34%).
The large relative and absolute risk reductions observed supports IPE as an important therapeutic option for patients with metabolic syndrome at high cardiovascular risk, despite lacking robust effects on any metabolic syndrome component.
“These subgroup findings provide us with valuable insight into the role icosapent ethyl may play in helping reduce the risk of cardiovascular events in patients with Metabolic Syndrome, but without concomitant diabetes, including those secondary prevention patients with established cardiovascular disease, a patient group particularly at high-risk of having another cardiovascular event,” said Michael Miller, M.D., cardiologist and Chief of Medicine, Corporal Michael J Crescenz Veterans Affairs Medical Center and Professor of Medicine, Hospital of the University of Pennsylvania in Philadelphia. “This is an area of growing concern for the medical community and for patients globally, given the steady rise in the number of patients with Metabolic Syndrome across the U.S. and around the world.”
Commenting on the findings, Amarin’s Chief Medical Officer Nabil Abadir said, “These data continue to reinforce the clinical value of IPE and expand the growing list of benefits attributable to the molecule, including secondary prevention patients such as those with prior myocardial infarction, percutaneous coronary intervention or coronary bypass grafting, chronic kidney disease, heart failure, and history of cigarette smoking.”
Limitations of these analyses, some of which are exploratory in nature, include the relatively small number of events in certain subgroups or for certain endpoints, such as cardiac arrest and sudden cardiac death. In addition, variation in subjective measures (e.g., waist circumference) may have affected classification of metabolic syndrome.
About Metabolic Syndrome
Metabolic Syndrome is a cluster of conditions that increase the risk of heart disease, stroke and Type 2 diabetes mellitus (T2DM). Metabolic Syndrome is defined as the presence of any three of the following five risk factors: increased blood pressure, high blood sugar, excess body fat around the waist, low HDL cholesterol, or elevated/high triglyceride levels.1 Metabolic Syndrome is increasingly common,1 and more than 1 out of 3 people in the United States have it. Metabolic Syndrome is not only associated with a two-fold increased risk of adverse cardiovascular disease (CVD) outcomes (e.g., myocardial infarction, stroke and CV mortality), even in the absence of T2DM, but in recent years has also been linked to a variety of pathogenic phenotypes including heart failure and renal insufficiency.2,3,4
About Cardiovascular Risk
Cardiovascular disease is the number one cause of death in the world. In the United States alone, cardiovascular disease results in 859,000 deaths per year,5 and the number of deaths in the United States attributed to cardiovascular disease continues to rise. In addition, in the United States there are 605,000 new and 200,000 recurrent heart attacks per year (approximately 1 every 40 seconds). Stroke rates are 795,000 per year (approximately 1 every 40 seconds), accounting for 1 of every 19 U.S. deaths. In aggregate, in the United States alone, there are more than 2.4 million major adverse cardiovascular events per year from cardiovascular disease or, on average, 1 every 13 seconds.
Controlling bad cholesterol, also known as LDL-C, is one way to reduce a patient’s risk for cardiovascular events, such as heart attack, stroke or death. However, even with the achievement of target LDL-C levels, millions of patients still have significant and persistent risk of cardiovascular events, especially those patients with elevated triglycerides. Statin therapy has been shown to control LDL-C, thereby reducing the risk of cardiovascular events by 25-35%.6 Significant cardiovascular risk remains after statin therapy. People with elevated triglycerides have 35% more cardiovascular events compared to people with normal (in range) triglycerides taking statins.7,8,9
About REDUCE-IT®
REDUCE-IT was a global cardiovascular outcomes study designed to evaluate the effect of VASCEPA in adult patients with LDL-C controlled to between 41-100 mg/dL (median baseline 75 mg/dL) by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides between 135-499 mg/dL (median baseline 216 mg/dL) and either established cardiovascular disease (secondary prevention cohort) or diabetes mellitus and at least one other cardiovascular risk factor (primary prevention cohort).
REDUCE-IT, conducted over seven years and completed in 2018, followed 8,179 patients at over 400 clinical sites in 11 countries with the largest number of sites located within the United States. REDUCE-IT was conducted based on a special protocol assessment agreement with FDA. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology.10 The primary results of REDUCE-IT were published in The New England Journal of Medicine in November 201811. The total events 12 and other publications can be found in the R&D section on the company’s website at www.amarincorp.com.
About VASCEPA®/VAZKEPA® (icosapent ethyl) Capsules
VASCEPA (icosapent ethyl) capsules are the first prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk despite being on statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed more than twenty million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, VASCEPA is approved and sold in Canada, China, Lebanon and the United Arab Emirates. In Europe, in March 2021 marketing authorization was granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA. In April 2021 marketing authorization for VAZKEPA (icosapent ethyl) was granted in Great Britain (applying to England, Scotland and Wales). VAZKEPA (icosapent ethyl) is currently approved and sold in Europe in Sweden, Denmark, Finland, Austria, the UK, Spain and the Netherlands.
Indications and Limitation of Use (in the United States)
VASCEPA is indicated:
As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and
established cardiovascular disease or
diabetes mellitus and two or more additional risk factors for cardiovascular disease.
As an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
Important Safety Information
VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.
VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter.
It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur.
VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin.
Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial fibrillation (5% vs 4%).
Common adverse reactions in the hypertriglyceridemia trials (incidence >1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%).
Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.
Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding.
FULL U.S. FDA-APPROVED VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.
Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about the potential for VASCEPA (marketed as VAZKEPA in Europe); beliefs about icosapent ethyl (IPE)’s potential role in helping reduce the risk of cardiovascular events in patients with Metabolic Syndrome, but without concomitant diabetes, as well as general beliefs about the safety and effectiveness of VASCEPA/VAZKEPA. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the full year ended 2022. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate. Availability of Other Information About Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Lowest price ever.
ASTC 7.86 – 17%
As of September 26, 2023, 1,682,286 shares = MKTCAP: 13.2M
AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE)
Financial Highlights & Fiscal Year Developments
• Astrotech’s consolidated balance sheet remains strong with $42.1 million in cash and cash equivalents and liquid investments which is anticipated to support our research and development, organic growth, and potential acquisition targets.
• Gross margin increased to 41% for the year compared to 22% in the prior period, due to a higher proportion of recurring revenue.
The Board believes that BML’s aim is to realize a short-term gain at the expense of the Company’s other stockholders. The Board believes that BML’s strategy of potentially liquidating the Company, as stated in BML’s Schedule 13D, would result in unfair profits to BML at the expense of all other stockholders because the offer price of $17.25 per share is significantly less than the per share value of the Company’s cash and short-term equivalents. Consistent with its history involving other public companies, the Board believes BML is targeting Astrotech for liquidation because the market value of Astrotech’s common stock is less than the book value of its cash and short-term investments. If BML were to acquire the Company at $17.25 per share (excluding shares directly held by BML), BML would expend an aggregate $25 million for the remaining 87% of Company shares that it does not own, and BML would then own 100% of a Company with a value of $26.17 per share, based solely on the book value of the cash and short-term investments as of March 31, 2023. If BML were then to liquidate the Company shortly thereafter, BML would realize a gain on all of its shares that would represent a significant premium over what all other stockholders would receive based on the Proposal, to the sole benefit of BML.
Lowest price ever.
ASTC 7.86 – 17%
As of September 26, 2023, 1,682,286 shares = MKTCAP: 13.2M
AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE)
Financial Highlights & Fiscal Year Developments
• Astrotech’s consolidated balance sheet remains strong with $42.1 million in cash and cash equivalents and liquid investments which is anticipated to support our research and development, organic growth, and potential acquisition targets.
• Gross margin increased to 41% for the year compared to 22% in the prior period, due to a higher proportion of recurring revenue.
The Board believes that BML’s aim is to realize a short-term gain at the expense of the Company’s other stockholders. The Board believes that BML’s strategy of potentially liquidating the Company, as stated in BML’s Schedule 13D, would result in unfair profits to BML at the expense of all other stockholders because the offer price of $17.25 per share is significantly less than the per share value of the Company’s cash and short-term equivalents. Consistent with its history involving other public companies, the Board believes BML is targeting Astrotech for liquidation because the market value of Astrotech’s common stock is less than the book value of its cash and short-term investments. If BML were to acquire the Company at $17.25 per share (excluding shares directly held by BML), BML would expend an aggregate $25 million for the remaining 87% of Company shares that it does not own, and BML would then own 100% of a Company with a value of $26.17 per share, based solely on the book value of the cash and short-term investments as of March 31, 2023. If BML were then to liquidate the Company shortly thereafter, BML would realize a gain on all of its shares that would represent a significant premium over what all other stockholders would receive based on the Proposal, to the sole benefit of BML.
Amarin AMRN: 0.696
Pre-Market $0.76 + 0.064 (9.19%)
Total Cash (mrq) 321M
Total Cash Per Share (mrq) 0.79
Shares Outstanding 407.91M
Float 376.19M
Book Value Per Share (mrq) 1.39
company Reported Total Net Revenues of $66 Million in the Third Quarter 2023 --
-- Delivered Positive Cash Flow of $8 Million in the Quarter, Marking Fifth Consecutive Quarter of Cash Positive Operations1; Quarter-Ending Cash Position of $321 Million and no debt--
-- Company Continues to Deliver Significant U.S. Profit Through Extended Lifecycle and Market Leadership of Branded VASCEPA® --
-- Early Launch Progress in European Countries Driven by New Leadership --
“As we focus on demonstrating results that will drive shareholder value, there are reasons to be optimistic about the future of Amarin,” said Patrick Holt, President & CEO of Amarin. “We have a strong balance sheet, with $321 million in cash, including five consecutive quarters of positive cash flow and no debt.
Amarin AMRN: 0.696
Pre-Market $0.76 + 0.064 (9.19%)
Total Cash (mrq) 321M
Total Cash Per Share (mrq) 0.79
Shares Outstanding 407.91M
Float 376.19M
Book Value Per Share (mrq) 1.39
company Reported Total Net Revenues of $66 Million in the Third Quarter 2023 --
-- Delivered Positive Cash Flow of $8 Million in the Quarter, Marking Fifth Consecutive Quarter of Cash Positive Operations1; Quarter-Ending Cash Position of $321 Million and no debt--
-- Company Continues to Deliver Significant U.S. Profit Through Extended Lifecycle and Market Leadership of Branded VASCEPA® --
-- Early Launch Progress in European Countries Driven by New Leadership --
“As we focus on demonstrating results that will drive shareholder value, there are reasons to be optimistic about the future of Amarin,” said Patrick Holt, President & CEO of Amarin. “We have a strong balance sheet, with $321 million in cash, including five consecutive quarters of positive cash flow and no debt.
Time for a strong recovery
RCON : 0.25
52 Week Range 0.2500 - 2.1300
Shares Outstanding 38.53M
Market Cap : 9.63M
As of June 30, 2023, we had cash in the amount of approximately RMB104.1 million ($14.4 million) and short-term investment in bank fixed income product of approximately RMB184.2 million ($25.4 million). = 39.8M
Total Assets $ 73,341,964
Total Liabilities $ 12,780,285
= More than $ 60,000,000
Recon Technology, Ltd. is a provider of hardware, software and on-site services to companies in the petroleum mining and extraction industry in China, the People's Republic of China. The Company provides services designed to automate and enhance the extraction of petroleum. The Company controls by contract the People's Republic of China companies of Beijing BHD Petroleum Technology Co., Ltd. (BHD) and Nanjing Recon Technology Co., Ltd. It serves as the center of strategic management, financial control and human resources allocation for the Domestic Companies. Through its contractual relationships with the Domestic Companies, it provides equipment, tools and other hardware related to oilfield production and management, and develops and sells its specialized industrial automation control and information solutions. Its products and services include Equipment for Oil and Gas Production and Transportation, Oil and Gas Production Improvement Techniques, and Automation System and Service.
https://www.recon.cn
Time for a strong recovery
RCON : 0.25
52 Week Range 0.2500 - 2.1300
Shares Outstanding 38.53M
Market Cap : 9.63M
As of June 30, 2023, we had cash in the amount of approximately RMB104.1 million ($14.4 million) and short-term investment in bank fixed income product of approximately RMB184.2 million ($25.4 million). = 39.8M
Total Assets $ 73,341,964
Total Liabilities $ 12,780,285
= More than $ 60,000,000
Recon Technology, Ltd. is a provider of hardware, software and on-site services to companies in the petroleum mining and extraction industry in China, the People's Republic of China. The Company provides services designed to automate and enhance the extraction of petroleum. The Company controls by contract the People's Republic of China companies of Beijing BHD Petroleum Technology Co., Ltd. (BHD) and Nanjing Recon Technology Co., Ltd. It serves as the center of strategic management, financial control and human resources allocation for the Domestic Companies. Through its contractual relationships with the Domestic Companies, it provides equipment, tools and other hardware related to oilfield production and management, and develops and sells its specialized industrial automation control and information solutions. Its products and services include Equipment for Oil and Gas Production and Transportation, Oil and Gas Production Improvement Techniques, and Automation System and Service.
https://www.recon.cn
VJET: 1.24
52w: 1.02 – 3.40
voxeljet Showcases Its Next-Gen 3D Printers VJET X in Action at BMW Group: With 10x Faster Performance, the New 3D Printers Are Integrated Into a Fully Automated Additive Production Line
Wed, October 25, 2023 at 3:15 PM
voxeljet's 3D printers significantly reduce emissions in the additive manufacturing process of metal parts and make new designs possible
• voxeljet and Loramendi jointly developed a fully-automated serial additive production solution for inorganic 3D printed cores as part of the Industrialization of Core Printing (ICP) cooperation project
• BMW Group so far has implemented five VX1300-X (VJET-X) 3D printers for light-metal casting to produce high-performance engines at its plant in Landshut, Germany
• 10x faster than previous models, VJET-X printers will produce hundreds of thousands of cores per year for BMW Group
• Link to video:
VJET: 1.24
52w: 1.02 – 3.40
voxeljet Showcases Its Next-Gen 3D Printers VJET X in Action at BMW Group: With 10x Faster Performance, the New 3D Printers Are Integrated Into a Fully Automated Additive Production Line
Wed, October 25, 2023 at 3:15 PM
voxeljet's 3D printers significantly reduce emissions in the additive manufacturing process of metal parts and make new designs possible
• voxeljet and Loramendi jointly developed a fully-automated serial additive production solution for inorganic 3D printed cores as part of the Industrialization of Core Printing (ICP) cooperation project
• BMW Group so far has implemented five VX1300-X (VJET-X) 3D printers for light-metal casting to produce high-performance engines at its plant in Landshut, Germany
• 10x faster than previous models, VJET-X printers will produce hundreds of thousands of cores per year for BMW Group
• Link to video:
ReShape Lifesciences, Inc.
RSLS: soon FDA approval
Total Cash (mrq) 4.57M
Total Cash Per Share (mrq) 1.32
Short % of Shares Outstanding (Oct 12, 2023) 18.00%
ReShape Lifesciences, Inc.
RSLS: soon FDA approval
Total Cash (mrq) 4.57M
Total Cash Per Share (mrq) 1.32
Short % of Shares Outstanding (Oct 12, 2023) 18.00%
The cheapest european stock
NEOVACS : 0.0003
Number of Neovacs shares outstanding 691,803,541
= marketcap: 207.541 euro
Euronext Growth Paris
FR001400HDX0 – Stock
Neovacs: The prospect of a major contract for Pharnext validates Neovacs’ investment strategy
October 23, 2023 at 08:05
Suresnes, October 23, 2023 – 8 a.m. CET - Néovacs (Euronext Growth Paris: ALNEV) provides an update on its investment strategy following the latest announcements from its subsidiary, Pharnext, a biopharmaceutical company at an advanced clinical stage developing a drug candidate for Charcot-Marie-Tooth disease type 1A (CMT1A).
As a reminder, in spring 2020, Néovacs unveiled a new strategic roadmap based on the continuation of internal research programs and, at the same time, the implementation of an investment policy in BioTech and MedTech companies. . This policy makes it possible to diversify the potential sources of income for Néovacs, thus contributing to reducing the risk profile, and bringing value to the investments through the experience and scientific, managerial and financial knowledge of the Néovacs teams.
In this context, Pharnext constitutes by far the most promising investment, thanks to its advanced clinical stage (Phase III study completed awaiting the first results in a few weeks), the amount of sums invested to date (€21.1 million ) and its status as a listed company.
This potential was confirmed this Monday through the announcement, by Pharnext, of the receipt of two binding offers with a view to the signing of an agreement allowing the valuation of its most advanced drug candidate currently in development at more than €250 million. pivotal Phase III clinical study (PREMIER trial) in Charcot-Marie-Tooth disease type 1A (CMT1A), a rare debilitating peripheral neuropathy[1].
Under the terms of the partnership between Néovacs and Pharnext, Néovacs could receive remuneration indexed to the proceeds from the sale of all or part of Pharnext's assets (15% of the amount if it is greater than €1 million) or to revenues. a license (also 15%). In addition, Néovacs has share subscription warrants allowing it, from the beginning of 2024, to take up to 30% of the capital of Pharnext for an additional investment of €20 million. Based on the latest financial analysis published by research firm Edison, the total value of Pharnext's assets is estimated at €214 million.
Hugo Brugière, CEO of Néovacs, declares: “The favorable outcome that is emerging for Pharnext in the discussions around the valuation of its assets is excellent news in more than one way. For Pharnext, first, that we managed to get out of the strategic and financial impasse in which the company found itself at the end of 2022. For Néovacs, then, which will be able to demonstrate its ability to create value for its policy of investment. For the world of French biotechs, finally, which confirm the power of their innovation and their ability, provided they are well managed, to negotiate deals worth hundreds of millions of euros. »
ABOUT NEOVACS
Néovacs is a French biotechnology company, listed on Euronext Growth since 2010, specializing in therapeutic vaccines targeting the treatment of autoimmune diseases. Its innovative technology called Kinoid®, patented until 2038, makes it possible to induce a polyclonal immune response, applicable in several indications. Neovacs has developed IFNa Kinoid for the treatment of lupus in a phase IIb clinical study. The main study has been completed, full results were presented at the 13th International Lupus Congress 2019. The Company has also completed promising preclinical work with another therapeutic vaccine, IL-4/IL-13 Kinoid, for the treatment of allergies. The ambition of this “Kinoid® approach” is to enable patients to better tolerate a lifelong treatment that would be more effective, well tolerated and very flexible in its administration. For more information: www.neovacs.fr
The cheapest european stock
NEOVACS : 0.0003
Number of Neovacs shares outstanding 691,803,541
= marketcap: 207.541 euro
Euronext Growth Paris
FR001400HDX0 – Stock
Neovacs: The prospect of a major contract for Pharnext validates Neovacs’ investment strategy
October 23, 2023 at 08:05
Suresnes, October 23, 2023 – 8 a.m. CET - Néovacs (Euronext Growth Paris: ALNEV) provides an update on its investment strategy following the latest announcements from its subsidiary, Pharnext, a biopharmaceutical company at an advanced clinical stage developing a drug candidate for Charcot-Marie-Tooth disease type 1A (CMT1A).
As a reminder, in spring 2020, Néovacs unveiled a new strategic roadmap based on the continuation of internal research programs and, at the same time, the implementation of an investment policy in BioTech and MedTech companies. . This policy makes it possible to diversify the potential sources of income for Néovacs, thus contributing to reducing the risk profile, and bringing value to the investments through the experience and scientific, managerial and financial knowledge of the Néovacs teams.
In this context, Pharnext constitutes by far the most promising investment, thanks to its advanced clinical stage (Phase III study completed awaiting the first results in a few weeks), the amount of sums invested to date (€21.1 million ) and its status as a listed company.
This potential was confirmed this Monday through the announcement, by Pharnext, of the receipt of two binding offers with a view to the signing of an agreement allowing the valuation of its most advanced drug candidate currently in development at more than €250 million. pivotal Phase III clinical study (PREMIER trial) in Charcot-Marie-Tooth disease type 1A (CMT1A), a rare debilitating peripheral neuropathy[1].
Under the terms of the partnership between Néovacs and Pharnext, Néovacs could receive remuneration indexed to the proceeds from the sale of all or part of Pharnext's assets (15% of the amount if it is greater than €1 million) or to revenues. a license (also 15%). In addition, Néovacs has share subscription warrants allowing it, from the beginning of 2024, to take up to 30% of the capital of Pharnext for an additional investment of €20 million. Based on the latest financial analysis published by research firm Edison, the total value of Pharnext's assets is estimated at €214 million.
Hugo Brugière, CEO of Néovacs, declares: “The favorable outcome that is emerging for Pharnext in the discussions around the valuation of its assets is excellent news in more than one way. For Pharnext, first, that we managed to get out of the strategic and financial impasse in which the company found itself at the end of 2022. For Néovacs, then, which will be able to demonstrate its ability to create value for its policy of investment. For the world of French biotechs, finally, which confirm the power of their innovation and their ability, provided they are well managed, to negotiate deals worth hundreds of millions of euros. »
ABOUT NEOVACS
Néovacs is a French biotechnology company, listed on Euronext Growth since 2010, specializing in therapeutic vaccines targeting the treatment of autoimmune diseases. Its innovative technology called Kinoid®, patented until 2038, makes it possible to induce a polyclonal immune response, applicable in several indications. Neovacs has developed IFNa Kinoid for the treatment of lupus in a phase IIb clinical study. The main study has been completed, full results were presented at the 13th International Lupus Congress 2019. The Company has also completed promising preclinical work with another therapeutic vaccine, IL-4/IL-13 Kinoid, for the treatment of allergies. The ambition of this “Kinoid® approach” is to enable patients to better tolerate a lifelong treatment that would be more effective, well tolerated and very flexible in its administration. For more information: www.neovacs.fr
VERY HUGH CONTRACT
VJET: 1.52
52 Week Range 1.0200 - 3.4000
Shares Outstanding 9.13M
Float 8 6.03M
voxeljet Selected for $14.9M Contract Alongside GE Research to Develop Advanced Manufacturing Technologies to Enable the U.S. Energy Transition
• Wed, October 11, 2023 at 3:15 PM GMT+2
•
• The DoE grant will fund the development and commercialization of a voxeljet (NASDAQ: VJET) sand binder jet 3D printer used to manufacture massive sand-casting molds
• The new manufacturing technology will produce metallic near net shape (NNS) components for the wind and hydro energy sectors, reducing production time and costs
• voxeljet will develop and build a 3D sand printer with breakthrough size for the additive manufacturing of sand molds for casting parts ranging from 10 tons to over 60 tons
FRIEDBERG, Germany, October 11, 2023--(BUSINESS WIRE)--GE Research has selected voxeljet (NASDAQ: VJET) as its partner for the U.S. Department of Energy’s (DoE) $14.9 million award in federal funding for the development and commercialization of a large sand binder jet 3D printer, called Advanced Casting Cell (ACC), to accelerate the United States’ transition to clean power. In addition to voxeljet, GE Research has also selected GE Hydro, GE Onshore Wind, GE Offshore Wind, Clemson University, Oak Ridge National Laboratory (ORNL), and Hodge Foundry as partners on the ACC project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231011327841/en/
Offshore Windturbine from GE Renewable Energy (© GE Renewable Energy) (Photo: Business Wire)
The Advanced Casting Cell project was established to strengthen the U.S. manufacturing industry and expertise to boost the cost-effective domestic production of large metallic near net shape (NNS) components in alignment of the Biden Administration’s clean power-generation strategy. The ACC will be developed and deployed to produce sand molds to manufacture metallic NNS parts. With development of the ACC, the project includes the digital creation of mold designs via a digital foundry as well as the completion of a techno-economic analysis of cost and supply chain challenges.
The project aims to produce 3D-printed large scale sand molds to cast components for the nacelle of the GE Haliade-X Offshore Turbine. The nacelle, where mechanical components are housed, can weigh more than 60 metric tons. The goal is to reduce the time it takes to produce this pattern and mold, from around ten weeks to two weeks. According to Data Bridge Market Research, the global wind turbine nacelle market has estimated to be valued at $6.6 billion in 2021 and projected to be over $15 billion by 2029.
This novel manufacturing technology has the potential to reduce overall hydropower costs by 20% and lead times by four months. The project will also include the production optimization of a 16-ton rotor hub using the ACC as well as the development of a robotic welding process for the assembly of a >10-ton Francis runner. To help ensure successful implementation of ACC, an advanced manufacturing curriculum is being created for local workforce development to train and engage workers on the specifics of this 3D printing manufacturing technology.
"We’re excited to be a part of this future-driven and innovative project," said Dr. Ingo Ederer, CEO of voxeljet. "The development and cost-efficient manufacturing of clean power-generation technologies is in high-demand because it is key to meeting and overcoming global climate challenges. We are confident that additive manufacturing, and specifically our large-scale Binder Jetting technology, is the right choice to manufacture complex parts used in these next-generation wind turbines."
About voxeljet
voxeljet’s (NASDAQ: VJET) roots reach back to the year 1995 with the first successful dosing of UV-resins. In the context of a "hidden" project, initial 3D-printing tests are performed at the Technical University Munich. Our company was founded on May 5, 1999 as a spin-off from TUM in Munich with a clear vision in mind: to establish a new manufacturing standard by developing new generative processes for the series-production of complex components using 3D printing. In the beginning, operations are launched with four employees at the TUM. Today, we are a globally acting, leading provider of high-speed, large-format 3D printers and on-demand 3D printed parts to industrial and commercial customers. Components manufactured with the help of our technology are flying in space, make mobility more efficient and the production of new engineering solutions possible. Visit our website www.voxeljet.com, and follow us on Linkedin, or on Twitter.
Cautionary Statement on Forward-Looking Statements
This press release contains forward-looking statements concerning our business, operations and financial performance. Any statements that are not of historical facts may be deemed forward-looking statements. You can identify these forward-looking statements by words such as ‘‘believes,’’ ‘‘estimates,’’ ‘‘anticipates,’’ ‘‘expects,’’ ‘‘plans,’’ ‘‘intends,’’ ‘‘may,’’ ‘‘could,’’ ‘‘might,’’ ‘‘will,’’ ‘‘should,’’ ‘‘aims,’’ "projects" or other similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements include statements regarding our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations concerning, among other things, our results of operations, financial condition, business outlook, the potential timeline for development of and application of new technology and new materials and their impact on future business, the industry in which we operate and the trends that may affect the industry or us. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that forward-looking statements are not guarantees of future performance. All of our forward-looking statements are subject to known and unknown risks, uncertainties and other factors that are in some cases beyond our control and that may cause our actual results to differ materially from our expectations, including those risks identified under the caption "Risk Factors" in voxeljet’s Annual Report on Form 20-F and in other reports voxeljet files with the U.S. Securities and Exchange Commission. Except as required by law, voxeljet undertakes no obligation to publicly update any forward-looking statements for any reason after the date of this press release whether as a result of new information, future events or otherwise.
VERY HUGH CONTRACT
VJET: 1.52
52 Week Range 1.0200 - 3.4000
Shares Outstanding 9.13M
Float 8 6.03M
voxeljet Selected for $14.9M Contract Alongside GE Research to Develop Advanced Manufacturing Technologies to Enable the U.S. Energy Transition
• Wed, October 11, 2023 at 3:15 PM GMT+2
•
• The DoE grant will fund the development and commercialization of a voxeljet (NASDAQ: VJET) sand binder jet 3D printer used to manufacture massive sand-casting molds
• The new manufacturing technology will produce metallic near net shape (NNS) components for the wind and hydro energy sectors, reducing production time and costs
• voxeljet will develop and build a 3D sand printer with breakthrough size for the additive manufacturing of sand molds for casting parts ranging from 10 tons to over 60 tons
FRIEDBERG, Germany, October 11, 2023--(BUSINESS WIRE)--GE Research has selected voxeljet (NASDAQ: VJET) as its partner for the U.S. Department of Energy’s (DoE) $14.9 million award in federal funding for the development and commercialization of a large sand binder jet 3D printer, called Advanced Casting Cell (ACC), to accelerate the United States’ transition to clean power. In addition to voxeljet, GE Research has also selected GE Hydro, GE Onshore Wind, GE Offshore Wind, Clemson University, Oak Ridge National Laboratory (ORNL), and Hodge Foundry as partners on the ACC project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231011327841/en/
Offshore Windturbine from GE Renewable Energy (© GE Renewable Energy) (Photo: Business Wire)
The Advanced Casting Cell project was established to strengthen the U.S. manufacturing industry and expertise to boost the cost-effective domestic production of large metallic near net shape (NNS) components in alignment of the Biden Administration’s clean power-generation strategy. The ACC will be developed and deployed to produce sand molds to manufacture metallic NNS parts. With development of the ACC, the project includes the digital creation of mold designs via a digital foundry as well as the completion of a techno-economic analysis of cost and supply chain challenges.
The project aims to produce 3D-printed large scale sand molds to cast components for the nacelle of the GE Haliade-X Offshore Turbine. The nacelle, where mechanical components are housed, can weigh more than 60 metric tons. The goal is to reduce the time it takes to produce this pattern and mold, from around ten weeks to two weeks. According to Data Bridge Market Research, the global wind turbine nacelle market has estimated to be valued at $6.6 billion in 2021 and projected to be over $15 billion by 2029.
This novel manufacturing technology has the potential to reduce overall hydropower costs by 20% and lead times by four months. The project will also include the production optimization of a 16-ton rotor hub using the ACC as well as the development of a robotic welding process for the assembly of a >10-ton Francis runner. To help ensure successful implementation of ACC, an advanced manufacturing curriculum is being created for local workforce development to train and engage workers on the specifics of this 3D printing manufacturing technology.
"We’re excited to be a part of this future-driven and innovative project," said Dr. Ingo Ederer, CEO of voxeljet. "The development and cost-efficient manufacturing of clean power-generation technologies is in high-demand because it is key to meeting and overcoming global climate challenges. We are confident that additive manufacturing, and specifically our large-scale Binder Jetting technology, is the right choice to manufacture complex parts used in these next-generation wind turbines."
About voxeljet
voxeljet’s (NASDAQ: VJET) roots reach back to the year 1995 with the first successful dosing of UV-resins. In the context of a "hidden" project, initial 3D-printing tests are performed at the Technical University Munich. Our company was founded on May 5, 1999 as a spin-off from TUM in Munich with a clear vision in mind: to establish a new manufacturing standard by developing new generative processes for the series-production of complex components using 3D printing. In the beginning, operations are launched with four employees at the TUM. Today, we are a globally acting, leading provider of high-speed, large-format 3D printers and on-demand 3D printed parts to industrial and commercial customers. Components manufactured with the help of our technology are flying in space, make mobility more efficient and the production of new engineering solutions possible. Visit our website www.voxeljet.com, and follow us on Linkedin, or on Twitter.
Cautionary Statement on Forward-Looking Statements
This press release contains forward-looking statements concerning our business, operations and financial performance. Any statements that are not of historical facts may be deemed forward-looking statements. You can identify these forward-looking statements by words such as ‘‘believes,’’ ‘‘estimates,’’ ‘‘anticipates,’’ ‘‘expects,’’ ‘‘plans,’’ ‘‘intends,’’ ‘‘may,’’ ‘‘could,’’ ‘‘might,’’ ‘‘will,’’ ‘‘should,’’ ‘‘aims,’’ "projects" or other similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements include statements regarding our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations concerning, among other things, our results of operations, financial condition, business outlook, the potential timeline for development of and application of new technology and new materials and their impact on future business, the industry in which we operate and the trends that may affect the industry or us. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that forward-looking statements are not guarantees of future performance. All of our forward-looking statements are subject to known and unknown risks, uncertainties and other factors that are in some cases beyond our control and that may cause our actual results to differ materially from our expectations, including those risks identified under the caption "Risk Factors" in voxeljet’s Annual Report on Form 20-F and in other reports voxeljet files with the U.S. Securities and Exchange Commission. Except as required by law, voxeljet undertakes no obligation to publicly update any forward-looking statements for any reason after the date of this press release whether as a result of new information, future events or otherwise.
ReShape Lifesciences Inc. (RSLS) premarket: 1.02 + 277%
52w high: 22.40
As of August 3, 2023, 3,452,447 shares of the registrant’s Common Stock were outstanding.
Float : 2.54M
Book Value Per Share (mrq) 7.05
https://www.reshapelifesciences.com/lapbandvideos/
MATTHEW NACHTRAB REPORTS 27.7% STAKE IN RESHAPE LIFESCIENCES AS
NACHTRAB-PURCHASED CO'S COMMON STOCK BASED ON BELIEF THAT SUCH SECURITIES, AT CURRENT MARKET PRICES, REPRESENTED AN ATTRACTIVE INVESTMENT OPPORTUNITY
NACHTRAB - WROTE A LETTER TO THE CEO OF CO WITH RECOMMENDATIONS FOR THE MANAGEMENT TEAM’S STRATEGY GOING FORWARD
I am excited for your new tenure as CEO of ReShape Lifesciences and I believe your team can rebuild and create a $100m plus market cap company with some austerity measures, leveraging assets currently owned, and capitalizing on the medicated weight loss secular trend to generate lead flow and massive revenue growth. I am willing to discuss this and advise in any way I can help.
Jan 30, 2023 8.1400 22.4000 6.0600 17.0400 17.0400 12,624,600
Jan 02, 2023 9.6600 20.6300 7.0800 7.2600 7.2600 13,614,600
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
ReShape Lifesciences Inc. (RSLS) premarket: 1.02 + 277%
52w high: 22.40
As of August 3, 2023, 3,452,447 shares of the registrant’s Common Stock were outstanding.
Float : 2.54M
Book Value Per Share (mrq) 7.05
https://www.reshapelifesciences.com/lapbandvideos/
MATTHEW NACHTRAB REPORTS 27.7% STAKE IN RESHAPE LIFESCIENCES AS
NACHTRAB-PURCHASED CO'S COMMON STOCK BASED ON BELIEF THAT SUCH SECURITIES, AT CURRENT MARKET PRICES, REPRESENTED AN ATTRACTIVE INVESTMENT OPPORTUNITY
NACHTRAB - WROTE A LETTER TO THE CEO OF CO WITH RECOMMENDATIONS FOR THE MANAGEMENT TEAM’S STRATEGY GOING FORWARD
I am excited for your new tenure as CEO of ReShape Lifesciences and I believe your team can rebuild and create a $100m plus market cap company with some austerity measures, leveraging assets currently owned, and capitalizing on the medicated weight loss secular trend to generate lead flow and massive revenue growth. I am willing to discuss this and advise in any way I can help.
Jan 30, 2023 8.1400 22.4000 6.0600 17.0400 17.0400 12,624,600
Jan 02, 2023 9.6600 20.6300 7.0800 7.2600 7.2600 13,614,600
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Taoping TAOP: $2.95 +0.94 (+46.77%)
Pre-Market Volume 511,607
Pre-Market High $3.58 (08:41:14 AM)
Pre-Market Low $2.22 (08:02:28 AM)
Shares Outstanding 5 1.97M
Float 1.33M
Book Value Per Share (mrq) 5.13
SHENZHEN, China, Oct. 12, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today reported a nearly 100% year-over-year increase in the Company's contract revenue value for its cloud-based product, software and advertising businesses in the first nine months of 2023. The Company entered into contracts totaling RMB 191 million (approximately US$26.55 million) during the first nine months of 2023, the revenues from which the Company expects to recognize within fiscal year 2023.
The surge in growth follows the 95% year-over-year increase in contract revenue value reported for the first six months of 2023. High demand for Taoping's city partner ecosystem and comprehensive portfolio of core high-value, high-traffic area software development and advertising business solutions continues to drive growth and leverage the Company's powerful new Cloud Nest AI system and intelligent Cloud platform.
Mr. Lin Jianghuai, Chairman and CEO of Taoping, said: "After the Company's record start to 2023, we had high expectations for our business in the post-pandemic environment. Travel and interest in outdoor activities are once again popular, causing governments and private enterprises to further increase spending and accelerate development timelines to accommodate the higher demand on facilities and public spaces. For Taoping, our commitment to expanding our integrated solutions ecosystem enables us to now capture a greater share of these expanded growth opportunities. We expect this momentum to continue through 2023 as we focus on profitable revenue growth and maximizing the return on the many new products and solutions we successfully launched over the past few quarters."
"We are particularly excited about the many growth opportunities for our off-grid wastewater solutions, given the critical need for smaller, easy-to-install, and highly effective yet more economical solutions like Taoping's, and our leading-edge Smart City solutions, which seamlessly integrate with our AI-driven intelligent Cloud platform. Given Taoping's strong year-to-date growth and outlook, we believe our share price is undervalued and does not fully reflect Taoping's fundamentals, impressive portfolio pipeline and the underlying value of our ecosystem of integrated solutions. We believe our continued focus on strategy execution and delivery of improved financial results will drive greater value for investors and lead to a higher share price that more accurately reflects the Company's long-term intrinsic value."
About Taoping Inc.
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us on X.
Taoping TAOP: $2.95 +0.94 (+46.77%)
Pre-Market Volume 511,607
Pre-Market High $3.58 (08:41:14 AM)
Pre-Market Low $2.22 (08:02:28 AM)
Shares Outstanding 5 1.97M
Float 1.33M
Book Value Per Share (mrq) 5.13
SHENZHEN, China, Oct. 12, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today reported a nearly 100% year-over-year increase in the Company's contract revenue value for its cloud-based product, software and advertising businesses in the first nine months of 2023. The Company entered into contracts totaling RMB 191 million (approximately US$26.55 million) during the first nine months of 2023, the revenues from which the Company expects to recognize within fiscal year 2023.
The surge in growth follows the 95% year-over-year increase in contract revenue value reported for the first six months of 2023. High demand for Taoping's city partner ecosystem and comprehensive portfolio of core high-value, high-traffic area software development and advertising business solutions continues to drive growth and leverage the Company's powerful new Cloud Nest AI system and intelligent Cloud platform.
Mr. Lin Jianghuai, Chairman and CEO of Taoping, said: "After the Company's record start to 2023, we had high expectations for our business in the post-pandemic environment. Travel and interest in outdoor activities are once again popular, causing governments and private enterprises to further increase spending and accelerate development timelines to accommodate the higher demand on facilities and public spaces. For Taoping, our commitment to expanding our integrated solutions ecosystem enables us to now capture a greater share of these expanded growth opportunities. We expect this momentum to continue through 2023 as we focus on profitable revenue growth and maximizing the return on the many new products and solutions we successfully launched over the past few quarters."
"We are particularly excited about the many growth opportunities for our off-grid wastewater solutions, given the critical need for smaller, easy-to-install, and highly effective yet more economical solutions like Taoping's, and our leading-edge Smart City solutions, which seamlessly integrate with our AI-driven intelligent Cloud platform. Given Taoping's strong year-to-date growth and outlook, we believe our share price is undervalued and does not fully reflect Taoping's fundamentals, impressive portfolio pipeline and the underlying value of our ecosystem of integrated solutions. We believe our continued focus on strategy execution and delivery of improved financial results will drive greater value for investors and lead to a higher share price that more accurately reflects the Company's long-term intrinsic value."
About Taoping Inc.
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us on X.
VERY HUGH CONTRACT
VJET: 1.5199 + 0.4899 (47.56%)
52 Week Range 1.0200 - 3.4000
Market Cap (intraday) 9.50M
Shares Outstanding 9.13M
Float 8 6.03M
voxeljet Selected for $14.9M Contract Alongside GE Research to Develop Advanced Manufacturing Technologies to Enable the U.S. Energy Transition
• Wed, October 11, 2023 at 3:15 PM GMT+2
•
• The DoE grant will fund the development and commercialization of a voxeljet (NASDAQ: VJET) sand binder jet 3D printer used to manufacture massive sand-casting molds
• The new manufacturing technology will produce metallic near net shape (NNS) components for the wind and hydro energy sectors, reducing production time and costs
• voxeljet will develop and build a 3D sand printer with breakthrough size for the additive manufacturing of sand molds for casting parts ranging from 10 tons to over 60 tons
FRIEDBERG, Germany, October 11, 2023--(BUSINESS WIRE)--GE Research has selected voxeljet (NASDAQ: VJET) as its partner for the U.S. Department of Energy’s (DoE) $14.9 million award in federal funding for the development and commercialization of a large sand binder jet 3D printer, called Advanced Casting Cell (ACC), to accelerate the United States’ transition to clean power. In addition to voxeljet, GE Research has also selected GE Hydro, GE Onshore Wind, GE Offshore Wind, Clemson University, Oak Ridge National Laboratory (ORNL), and Hodge Foundry as partners on the ACC project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231011327841/en/
Offshore Windturbine from GE Renewable Energy (© GE Renewable Energy) (Photo: Business Wire)
The Advanced Casting Cell project was established to strengthen the U.S. manufacturing industry and expertise to boost the cost-effective domestic production of large metallic near net shape (NNS) components in alignment of the Biden Administration’s clean power-generation strategy. The ACC will be developed and deployed to produce sand molds to manufacture metallic NNS parts. With development of the ACC, the project includes the digital creation of mold designs via a digital foundry as well as the completion of a techno-economic analysis of cost and supply chain challenges.
The project aims to produce 3D-printed large scale sand molds to cast components for the nacelle of the GE Haliade-X Offshore Turbine. The nacelle, where mechanical components are housed, can weigh more than 60 metric tons. The goal is to reduce the time it takes to produce this pattern and mold, from around ten weeks to two weeks. According to Data Bridge Market Research, the global wind turbine nacelle market has estimated to be valued at $6.6 billion in 2021 and projected to be over $15 billion by 2029.
This novel manufacturing technology has the potential to reduce overall hydropower costs by 20% and lead times by four months. The project will also include the production optimization of a 16-ton rotor hub using the ACC as well as the development of a robotic welding process for the assembly of a >10-ton Francis runner. To help ensure successful implementation of ACC, an advanced manufacturing curriculum is being created for local workforce development to train and engage workers on the specifics of this 3D printing manufacturing technology.
"We’re excited to be a part of this future-driven and innovative project," said Dr. Ingo Ederer, CEO of voxeljet. "The development and cost-efficient manufacturing of clean power-generation technologies is in high-demand because it is key to meeting and overcoming global climate challenges. We are confident that additive manufacturing, and specifically our large-scale Binder Jetting technology, is the right choice to manufacture complex parts used in these next-generation wind turbines."
About voxeljet
voxeljet’s (NASDAQ: VJET) roots reach back to the year 1995 with the first successful dosing of UV-resins. In the context of a "hidden" project, initial 3D-printing tests are performed at the Technical University Munich. Our company was founded on May 5, 1999 as a spin-off from TUM in Munich with a clear vision in mind: to establish a new manufacturing standard by developing new generative processes for the series-production of complex components using 3D printing. In the beginning, operations are launched with four employees at the TUM. Today, we are a globally acting, leading provider of high-speed, large-format 3D printers and on-demand 3D printed parts to industrial and commercial customers. Components manufactured with the help of our technology are flying in space, make mobility more efficient and the production of new engineering solutions possible. Visit our website www.voxeljet.com, and follow us on Linkedin, or on Twitter.
Cautionary Statement on Forward-Looking Statements
This press release contains forward-looking statements concerning our business, operations and financial performance. Any statements that are not of historical facts may be deemed forward-looking statements. You can identify these forward-looking statements by words such as ‘‘believes,’’ ‘‘estimates,’’ ‘‘anticipates,’’ ‘‘expects,’’ ‘‘plans,’’ ‘‘intends,’’ ‘‘may,’’ ‘‘could,’’ ‘‘might,’’ ‘‘will,’’ ‘‘should,’’ ‘‘aims,’’ "projects" or other similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements include statements regarding our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations concerning, among other things, our results of operations, financial condition, business outlook, the potential timeline for development of and application of new technology and new materials and their impact on future business, the industry in which we operate and the trends that may affect the industry or us. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that forward-looking statements are not guarantees of future performance. All of our forward-looking statements are subject to known and unknown risks, uncertainties and other factors that are in some cases beyond our control and that may cause our actual results to differ materially from our expectations, including those risks identified under the caption "Risk Factors" in voxeljet’s Annual Report on Form 20-F and in other reports voxeljet files with the U.S. Securities and Exchange Commission. Except as required by law, voxeljet undertakes no obligation to publicly update any forward-looking statements for any reason after the date of this press release whether as a result of new information, future events or otherwise.